Clinical Trial Update: Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014) [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics, safety, and tolerability of ertugliflozin in hepatic impairment and healthy individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus, Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2018-08-03